title: Immunosuppressive drugs in organ transplant recipients--rationale for critical selection.
abstract: Transplantation is the treatment of choice for many different organ failures. Despite growing experience in surgery and immunosuppression protocols, the long-term mortality of the procedure remains much higher than in the general population. Second only to cardiovascular diseases as the cause of death in organ transplant recipients, cancer is now known to be at least partly related to the immunosuppression regimen. Nevertheless, if calcineurin inhibitors have a demonstrated pro-oncogenic effect, other classes, such as mTOR inhibitors, are antiproliferative, and even demonstrated as an efficient therapy in some advanced oncological situations. Therefore, the adaptation of the therapy protocol evolves now towards an individualized medicine based on the risk factors of each transplant recipient in terms of cardiovascular, infectious and oncological diseases. As the first organ involved by tumor is the skin, many different guidelines have been published to try and adapt the therapy to the occurrence of a new lesion. If, for example, limited actinic keratosis or the first episode of a non-melanoma skin cancer usually requires no change of the immunosuppressive therapy, but a local specialized care and frequent clinical controls, more advanced lesions imply the adaptation of the drug regimen. In any case, the collaboration between general practitioners, dermatologists and the transplantation team is mandatory.
authors.affiliation: Department of Nephrology, Inselspital, Berne University Hospital and University of Bern, Bern, Switzerland. fabadt@gmail.com
authors.forename: Fabien
authors.initials: F
authors.lastname: Stucker
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Marti
authors.forename: Robert E
authors.initials: RE
authors.lastname: Hunger
mesh_terms: D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016377:Organ Transplantation / Q000379:methods; D057285:Precision Medicine; D012871:Skin Diseases / Q000209:etiology* / Q000517:prevention & control; D012878:Skin Neoplasms / Q000209:etiology
chemical_list: D007166:Immunosuppressive Agents